An observational study in Cerebral Vein Thrombosis and Cerebral Venous Sinus Thrombosis, sponsored by University Hospital, Akershus. Recruiting at 1 site in Norway. Per ClinicalTrials.gov, last updated 2025-02-05.
Sponsored by University Hospital, Akershus · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The NoCVT study will investigate CVT (2014-2023) in a large Norwegian population (> 3 millions) using several approaches combining existing health registries, clinical databases and new prospectively collected clinical data to explore epidemiology, risk factors, diagnostics, treatment, and the long-term prognosis of CVT.
A retrospective hospital-based chart review will be conducted at 13 different hospitals covering all four health regions and more than 3 million inhabitants in Norway. These 13 hospitals are Akershus University Hospital, Haukeland University Hospital. Oslo University Hospital (Ullevål), Sørlandet Hospital Kristiansand, Drammen Hospital, St.Olavs Hospital, Nordlandsykehuset Bodø, University Hospital of North Norway, Innlandet Hospital Lillehammer, Tønsberg Hospital, Telemark Hospital (Skien), Molde Hospital and Stavanger University Hospital.
A search will be made in the clinical database for patients with the relevant diagnosis of CVT in the period between January 1, 2014, and December 31, 2023. Data from hospital charts will be linked with data from Statistics Norway (SSB), FD-Trygd, and Norwegian Prescription Database (NorPD). Using this combination of clinical data and health registries will make it possible to describe risk factors, clinical and radiological presentation, treatment and short-term outcome in a large Norwegian CVT cohort.
Further, data from hospitals will be linked with data from SSB, FD-Trygd, NorPD, Norwegian Patient Registry (NPR) and Cause of Death Registry (DÅR) up to five years after CVT. Using this methodology will make it possible to investigate overall long-term prognosis and outcomes in terms of mortality, health care utilisation, medication use and working situation up to five years after CVT in a large Norwegian cohort.
Lastly, a prospective follow-up study will include patients that have been diagnosed with CVT at the NoCVT hospitals during 2019-2023. By combining the collected data from the retrospective hospital chart review with the new follow-up interviews and self-reported questionnaires it will be possible to describe quality of life, vocational outcomes, psychological distress, depression, insomnia and disease-related disability in CVT.
46 studies on the registry are indexed under Intracranial Thrombosis; 15 are open to participants now.
This study's planned enrollment of 600 is above the median of 319 across 26 observational studies indexed under Intracranial Thrombosis.
Browse Intracranial Thrombosis studies →University Hospital, Akershus is the lead sponsor of 125 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
A retrospective hospital-based chart review will be conducted at 13 different hospitals covering approximately 3 million inhabitants in Norway.
More precis, a validated ICD-10 search will be made in the clinical database for patients with the diagnosis of CVT in the period between January 1, 2014, and December 31, 2023. Data from the clinical databases at these hospitals will be linked with the mandatory National Health Registries for baseline data and prospectively collected follow-up data. The National Health Registries involved are Statistics Norway (SSB), Norwegian Prescription Database (NorPD), Norwegian Patient Registry (NPR) and Cause of Death Registry (DÅR).
In addition a clinical follow-up interview will be conducted with emphasis on long-term outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Mortality of CVT in a Norwegian population
Number dead vs total number of cases
Time frame: Baseline, 3 months, 12 months, 24 months and 5 years
Health care utilisation after CVT
Number of new health care system contacts among CVT cases
Time frame: Baseline to five years
Re-admission after CVT
Number of new re-admission among CVT cases
Time frame: Baseline to five years
New diagnosis after CVT
Type of new diagnosis among CVT cases
Time frame: Baseline to five years
New prescriptions after CVT
Type of new prescriptions among CVT cases
Time frame: Baseline to five years
Nursing home after CVT
Number of CVT cases in need for nursing home
Time frame: Baseline to five years
Use of anti-coagulation in the long-term after CVT
Number of cases with CVT using anti-coagulation
Time frame: Baseline to five years
Use of anti-platelet therapy in the long-term after CVT
Number of cases with CVT using anti-platelet therapy
Time frame: Baseline to five years
Use of painkillers in the long-term after CVT
Number of cases with CVT using painkillers
Time frame: Baseline to five years
Use of headache prophylactics in the long-term after CVT
Number of cases with CVT using headache prophylactics
Time frame: Baseline to five years
Use of anti-epileptic drugs in the long-term after CVT
Number of cases with CVT using anti-epileptic drugs
Time frame: Baseline to five years
Use of anti-depressants in the long-term after CVT
Number of cases with CVT using anti-epileptic drugs
Time frame: Baseline to five years
Sick-leave after CVT
Number of cases with CVT on sick-leave
Time frame: Baseline to five years
Disability pension after CVT
Number of cases with CVT on disability pension
Time frame: Baseline to five years
Headache after CVT
Type and frequency
Time frame: Baseline to five years
Headache-related quality of life after CVT
Migraine Disability Assessment Score and Headache Impact Test-6
Time frame: Baseline to five years
Seizure/epilepsy after CVT
Type and frequency
Time frame: Baseline to five years
Epilepsy-related quality of life after CVT
Quality of Life in Epilepsy Inventory-31
Time frame: Baseline to five years
Quality of life after CVT
EuroQoL 5
Time frame: Baseline to five years
Psychological distress after CVT
Patient Health Questionnaire-9 and Hospital Anxiety and Depression Scale
Time frame: Baseline to five years
Sleep problems after CVT
Bergen Insomnia Scale
Time frame: Baseline to five years
Plan to share: Undecided
Started Jan 2014 (actual). Primary completion is estimated for Dec 2026, 155 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Akershus →